Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma. (HOMIE-166)
Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma; a Prospective, Single-arm, Open Label, Multicenter Phase II Study: HOMIE-166.
Sponsor: Terumo Europe N.V.
Terminated
The HOMIE-166 clinical investigation was prematurely terminated due to sponsor's decision to permanently stop production of QuiremSpheres™ and QuiremScouts™.
Other terminated trials from Terumo Europe N.V.
More terminations from Terumo Europe N.V.
Other Hepatocellular Carcinoma trials with similar outcome
A NA clinical study on Hepatocellular Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Terumo Europe N.V. and has accumulated 6 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Sep 2024 — Sep 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Oct 2023 — Jul 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Dec 2022 — Oct 2023 [monthly]
Not Yet Recruiting NA
▶ Show 1 earlier version
-
Sep 2022 — Dec 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Terumo Europe N.V.
For direct contact, visit the study record on ClinicalTrials.gov .